The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.
A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
Novo redoubled its Victoza marketing efforts after a recent setback, and that's made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.
HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.
23andMe aired its first TV ad Monday, in a bid to build the audience for DNA sequencing.
Over the weekend, Publicis Omnicom vaulted past WPP to become the world's biggest ad holding company. The task now falls on its co-CEOs to sort out any conflicts and prevent defections.
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
Eli Lilly's GLP-1 drug is still in Phase III, but recently released data suggest it could be a formidable competitor to the already marketed GLP-1 drugs, including Novo's market-leading Victoza.
It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.
Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
Gwee, who pioneered pharma social media at Vertex before moving onto the agency side, is tasked with integrating digital and social strategies across the marketing and PR network's 14 agencies.
Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.
At first blush, Accenture's survey of pharma execs looks like more bad news for sales forces, but the firm tells MM&M that the sales overhauls are about more than reducing headcounts.
IMS Health has acquired Seattle-based software-as-a-service (SaaS) company Appature, the firms are expected to announce today.
Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief
Gift bans or no, students still connect with drug companies, a study has found.
An ePharma Summit panel of physicians takes the sheen off new marketing initiatives by telling pharmas they find them useless.
HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.
The company is beefing up its marketing staff, using an iPad-equipped mix of in-house and contracted talent.
Orexigen slashed its clinical trial recruitment period by 14 months using marketing tactics associated with retail.
A study on the effect that a medication's color and shape have on adherence gives short shrift to the marketing component that urges patients not to take medications that don't conform to doctors' orders
Facing lower-than-expected demand, Purdue and Transcept are broadening the commercial strategy for Intermezzo to include DTC and a larger selling force.
Emmy-winner Julie Bowen is part of the effort to spread allergy education and awareness in schools.
Google's latest data shows that the doctor-patient information divide isn't so much a divide as two parts of the same conversation.
Elsevier launches new drug class overviews, a whistleblower accuses Abbott and Genzyme clears the way for Lemtrada.
Following warnings that the worst might be coming, KV said Monday it will seek Chapter 11 bankruptcy protection.
The proposed changes center around non-cancer related pain and seek to alter how drug companies can talk about these pain meds.
Shire says the field of regenerative medicine is about to take off, and is building on the expertise acquired with Advanced BioHealing.